A Phase 1/2 interventional study of Isatuximab SAR650984 and Cemiplimab REGN2810 in Plasma Cell Myeloma, sponsored by Sanofi. Completed at 30 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-14.
Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Multiple Myeloma by Sanofi — 3 open to participants now, 8 under way, 3 of them phase 3. Multiple Myeloma · Sanofi.
Among the 39 studies in Multiple Myeloma by Sanofi, this one is the 10th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2018, is one of 3 in phase 1/2, and was the 25th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →3 of the 39 studies in Multiple Myeloma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Australia, Canada and 4 more countries
Ages 18+
Sanofi · Sites in United States, Australia, France and 6 more countries
Ages 18+
Sanofi · Sites in United States, Australia, Brazil and 14 more countries
Ages 18+
By country, each count listing its studies:
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 17 · Phase 3 7
First in 2002; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 56 across the 34 interventional studies, 423 across the 4 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
3 of the studies in Multiple Myeloma by Sanofi that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT06356571SanofiA Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | 2027-04-01 |
| NCT04643002SanofiIsatuximab in Combination With Novel Agents in RRMM - Master Protocol | 2027-09-13 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Multiple Myeloma by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objectives:
Secondary Objectives:
The duration of the study for a patient will include a period for screening of up to 21 days and 3-month post treatment follow up. The cycle duration is 28 days. Patients will continue treatment until disease progression, unacceptable adverse events, consent withdrawal, or any other reason.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have a known diagnosis of multiple myeloma with evidence of , as defined below:
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression. Cemiplimab on Days 1 and 15 in 28-day cycle up to disease progression.
Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810
Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression. Cemiplimab on Day 1 in 28-day cycle up to disease progression.
Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810
Isatuximab on Days 1, 8, 15 and 22, then Day 1 and 15 in 28-day cycles up to disease progression.
Drug: Isatuximab SAR650984
Pharmaceutical form: solution for infusion Route of administration: intravenous
Also known as: Sarclisa
Pharmaceutical form: solution for infusion Route of administration: intravenous
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
Potential DLTs were defined as the occurrence of any of the following adverse reactions at first treatment cycle, unless due to disease progression or obviously unrelated cause: Hematological DLTs: Grade(G) 4 neutropenia (N) for more than 7 consecutive days, G3 to G4 N complicated by fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 to G4 thrombocytopenia associated with clinically significant bleeding requiring clinical intervention or Non-hematological DLTs: G4 non-hematologic AE, G\>=2 uveitis, G3 non-hematological AE lasting greater than (\>)3 days despite optimal care support, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other AE that the investigator/study committee deemed to be dose-limiting, regardless of grade, was also considered as DLT.
Time frame: Cycle 1 Day 1 to Day 28
Phase 1 and Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered with a pharmaceutical product and which did not necessarily have a causal relationship with study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as an AE which occurred after the first dose of study treatment administration up to 30 days after the last dose of study treatment administration. The DLT observation period was 1 cycle (28 days). However, all AEs during treatment, unless due to disease progression or an obviously unrelated cause, were taken into consideration by the Study Committee for the determination of the maximum tolerated dose and recommended Phase 2 dose.
Time frame: TEAEs were collected from the first dose up to 30 days after the last dose of study treatment, approximately 50 months
Phase 2: Percentage of Participants With Overall Response Rate (ORR)
ORR by Investigator using international myeloma working group (IMWG) response criteria:percentage of participants with complete response (CR) (including stringent CR \[sCR\]very good partial response \[VGPR\] and partial response \[PR\]).CR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas,less than (\<)5% plasma cells in bone marrow (BM) aspirates and normal free light chain(FLC)ratio (0.26-1.65).sCR:CR plus no clonal cells in BM biopsy.VGPR:serum and urine M-protein detectable by immunofixation,not electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level\<100mg/24hour(h);FLC only:\>=90% decrease in difference between involved and uninvolved FLC levels.PR:\>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or \<200mg/24h.In addition to above, if present at baseline,\>=50% reduction in size (sum of products of maximal perpendicular diameters of measured lesions \[SPD\]) of soft tissue plasmacytomas required.
Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Phase 2: Percentage of Participants With Clinical Benefit Rate (CBR)
CBR by Investigator using IMWG response criteria: percentage of participants with CR (including sCR), VGPR, PR (all defined in previous OM) or MR. MR was defined as \>= 25% but \<= 49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%, which still exceeded 200 mg/24h; if present at baseline, \>=50% reduction in size (SPD) of soft tissue plasmacytomas was also required.
Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Phase 2: Duration of Follow-up
Duration of follow-up was defined as the date of randomization to the date of last contact or death, whichever came first. Median duration of follow-up is reported.
Time frame: From the date of randomization up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Phase 2: Duration of Response (DOR)
DOR: Time from date of first response (\>=PR) that was subsequently confirmed to date of first documented progressive disease (PD) or death.DOR was determined only for participants who achieved a response of PR or better.If progression or death not observed, participant was censored at date of last valid disease assessment not showing disease progression performed prior to initiating further anticancer treatment and analysis cut-off date.PD(IMWG criteria):increase of \>=25% from lowest confirmed value in any 1 of following:serum M-protein (absolute increase\>=0.5 gram/deciliter\[g/dL\]), serum M-protein increase\>=1g/dL if lowest M component \>=5g/dL; urine M-component (absolute increase \>=200mg/24h),appearance of new lesion(s),\>=50% increase from nadir in SPD of \>1 lesion or \>=50% increase in longest diameter of a previous lesion \>1cm in short axis,\>=50% increase in circulating plasma cells (minimum 200 cells/microliter\[c/mcL\]) if that was the only measure of disease. PR: as defined in OM3.
Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Phase 2: Time to Response (TTR)
TTR was defined as the time from randomization to first response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 hours. In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size SPD of soft tissue plasmacytomas was also required.
Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Phase 2: Progression Free Survival (PFS)
PFS: Time interval from the randomization date to the date of the first documented disease progression that is subsequently confirmed or the date of death due to any cause, whichever came first. If progression or death was not observed, participant was censored at date of last valid disease assessment not showing disease progression performed prior to initiation of a further anticancer treatment or the analysis cut-off date. Analysis was performed by Kaplan-Meier method. PD (IMWG) criteria: increase of \>=25% from lowest confirmed value in any 1 of following: serum M-protein (absolute increase \>=0.5g/dL), serum M-protein increase \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute increase \>=200mg/24h), appearance of new lesion(s),\>=50% increase from nadir in SPD of \>1 lesion or \>=50% increase in the longest diameter of a previous lesion \>1 cm in short axis or \>=50% increase in circulating plasma cells (minimum of 200 c/mcL) if that was the only measure of disease.
Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Phase 2: Overall Survival (OS)
OS was defined as the time interval from the date of randomization to death from any cause. Participants without death prior to the analysis cut-off date were censored at the last date the participant was known to be alive or the cut-off date, whichever came first. The results provided below corresponds to descriptive OS information at the time of primary analysis completion date of 09 October 2019.
Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Phase 1 and 2: Plasma Concentration Observed at the End of IV Infusion (Ceoi) of Isatuximab Alone and in Combination With Cemiplimab
Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of Ceoi. It was calculated using non-compartmental analysis (NCA) after the first administration in Cycle 1. The PK population was defined independently for isatuximab and cemiplimab and consisted of all participants from the all-treated (AT) population with at least 1 available concentration post-baseline (whatever the cycle and even if dosing was incomplete) with adequate documentation of dosing and sampling dates and times.
Time frame: At end of infusion (EOI) on Cycle 1 Day 1
Phase 1 and 2: Maximum Observed Concentration (Cmax) of Isatuximab Alone and in Combination With Cemiplimab
Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of Cmax. It was calculated using NCA after the first administration in Cycle 1.
Time frame: At start of infusion (SOI), EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1
Phase 1 and 2: Time to Reach Cmax (Tmax) of Isatuximab Alone and in Combination With Cemiplimab
Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of tmax. It was calculated using NCA after the first administration in Cycle 1.
Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1
Phase 1 and 2: Last Concentration Observed Above the Lower Limit of Quantitation (Clast) of Isatuximab Alone and in Combination With Cemiplimab
Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of Clast. It was calculated using NCA after the first administration in Cycle 1.
Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1
Phase 1 and 2: Time of Clast (Tlast) of Isatuximab Alone and in Combination With Cemiplimab
Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of tlast. It was calculated using NCA after the first administration in Cycle 1.
Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1
Phase 1 and 2: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Tlast (AUClast) of Isatuximab Alone and in Combination With Cemiplimab
AUClast was defined as the area under the plasma concentration versus time curve from time 0 to real time tlast calculated using the trapezoidal method over the dosing interval after the first administration in Cycle 1.
Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1
Phase 1 and 2: AUC From Time 0 to Week 1 (AUC1week) of Isatuximab Alone and in Combination With Cemiplimab
AUC1week was defined as the area under the plasma concentration versus time curve from time 0 to 1 week post dose calculated using the trapezoidal method over the dosing interval after the first administration in Cycle 1.
Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1
Phase 1 and 2: Number of Participants With Anti-Drug Antibodies (ADA) to Isatuximab
ADA responses were categorized as treatment-induced ADA and treatment boosted ADA. Pre-existing ADA was defined as ADA that were present in samples drawn during the pre-treatment period. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. The ADA evaluable population was defined independently for isatuximab and cemiplimab and consisted of all participants from AT population with at least 1 ADA result (negative, positive, or inconclusive) post-baseline.
Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 20 months
Phase 1 and 2: Number of Participants With ADA to Cemiplimab
ADA responses were categorized as treatment-induced ADA and treatment boosted ADA. Pre-existing ADA was defined as ADA that were present in samples drawn during the pre-treatment period. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer.
Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 20 months
Participants were screened at 30 sites. The study was conducted i.e. participants were randomized at 29 sites in 10 countries. A total of 3 participants in Phase 1 and 106 participants in Phase 2 were enrolled (Phase 1)/randomized (Phase 2) from 21 Feb 2018 to 20 Mar 2019.
| Milestone | Phase 1: Isatuximab + Cemiplimab Once Every 2 Weeks (Q2W) | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + Cemiplimab Once Every 4 Weeks (Q4W) |
|---|---|---|---|---|
| Started | 3 | 34 | 36 | 36 |
| Randomized and treated | 3 | 34 | 35 | 36 |
| Completed | 3 | 34 | 35 | 36 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Incorrect completion of end of study form | 0 | 0 | 1 | 0 |
Potential DLTs were defined as the occurrence of any of the following adverse reactions at first treatment cycle, unless due to disease progression or obviously unrelated cause: Hematological DLTs: Grade(G) 4 neutropenia (N) for more than 7 consecutive days, G3 to G4 N complicated by fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 to G4 thrombocytopenia associated with clinically significant bleeding requiring clinical intervention or Non-hematological DLTs: G4 non-hematologic AE, G\>=2 uveitis, G3 non-hematological AE lasting greater than (\>)3 days despite optimal care support, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other AE that the investigator/study committee deemed to be dose-limiting, regardless of grade, was also considered as DLT.
| Participants | Phase 1: Isatuximab + CemiplimabQ2W |
|---|---|
| Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) | 0 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered with a pharmaceutical product and which did not necessarily have a causal relationship with study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as an AE which occurred after the first dose of study treatment administration up to 30 days after the last dose of study treatment administration. The DLT observation period was 1 cycle (28 days). However, all AEs during treatment, unless due to disease progression or an obviously unrelated cause, were taken into consideration by the Study Committee for the determination of the maximum tolerated dose and recommended Phase 2 dose.
| Participants | Phase 1: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W |
|---|---|---|---|---|
| TEAEs | 3 | 33 | 36 | 33 |
| TESAEs | 1 | 17 | 17 | 21 |
ORR by Investigator using international myeloma working group (IMWG) response criteria:percentage of participants with complete response (CR) (including stringent CR \[sCR\]very good partial response \[VGPR\] and partial response \[PR\]).CR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas,less than (\<)5% plasma cells in bone marrow (BM) aspirates and normal free light chain(FLC)ratio (0.26-1.65).sCR:CR plus no clonal cells in BM biopsy.VGPR:serum and urine M-protein detectable by immunofixation,not electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level\<100mg/24hour(h);FLC only:\>=90% decrease in difference between involved and uninvolved FLC levels.PR:\>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or \<200mg/24h.In addition to above, if present at baseline,\>=50% reduction in size (sum of products of maximal perpendicular diameters of measured lesions \[SPD\]) of soft tissue plasmacytomas required.
| percentage of participants | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W |
|---|---|---|---|
| Phase 2: Percentage of Participants With Overall Response Rate (ORR) | 11.8 (3.30 to 27.45) | 25.0 (12.12 to 42.20) | 22.2 (10.12 to 39.15) |
CBR by Investigator using IMWG response criteria: percentage of participants with CR (including sCR), VGPR, PR (all defined in previous OM) or MR. MR was defined as \>= 25% but \<= 49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%, which still exceeded 200 mg/24h; if present at baseline, \>=50% reduction in size (SPD) of soft tissue plasmacytomas was also required.
| percentage of participants | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W |
|---|---|---|---|
| Phase 2: Percentage of Participants With Clinical Benefit Rate (CBR) | 23.5 (10.75 to 41.17) | 36.1 (20.82 to 53.78) | 38.9 (23.14 to 56.54) |
Duration of follow-up was defined as the date of randomization to the date of last contact or death, whichever came first. Median duration of follow-up is reported.
| months | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W |
|---|---|---|---|
| Phase 2: Duration of Follow-up | 10.28 (8.739 to 11.368) | 8.84 (8.016 to 11.072) | 9.03 (8.016 to 10.875) |
DOR: Time from date of first response (\>=PR) that was subsequently confirmed to date of first documented progressive disease (PD) or death.DOR was determined only for participants who achieved a response of PR or better.If progression or death not observed, participant was censored at date of last valid disease assessment not showing disease progression performed prior to initiating further anticancer treatment and analysis cut-off date.PD(IMWG criteria):increase of \>=25% from lowest confirmed value in any 1 of following:serum M-protein (absolute increase\>=0.5 gram/deciliter\[g/dL\]), serum M-protein increase\>=1g/dL if lowest M component \>=5g/dL; urine M-component (absolute increase \>=200mg/24h),appearance of new lesion(s),\>=50% increase from nadir in SPD of \>1 lesion or \>=50% increase in longest diameter of a previous lesion \>1cm in short axis,\>=50% increase in circulating plasma cells (minimum 200 cells/microliter\[c/mcL\]) if that was the only measure of disease. PR: as defined in OM3.
| months | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W |
|---|---|---|---|
| Phase 2: Duration of Response (DOR) | 5.6 (4 to 7) | 4.7 (3 to 12) | 5.7 (2 to 12) |
TTR was defined as the time from randomization to first response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 hours. In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size SPD of soft tissue plasmacytomas was also required.
| months | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W |
|---|---|---|---|
| Phase 2: Time to Response (TTR) | 1.5 (1 to 2) | 1.0 (1 to 3) | 1.0 (1 to 4) |
PFS: Time interval from the randomization date to the date of the first documented disease progression that is subsequently confirmed or the date of death due to any cause, whichever came first. If progression or death was not observed, participant was censored at date of last valid disease assessment not showing disease progression performed prior to initiation of a further anticancer treatment or the analysis cut-off date. Analysis was performed by Kaplan-Meier method. PD (IMWG) criteria: increase of \>=25% from lowest confirmed value in any 1 of following: serum M-protein (absolute increase \>=0.5g/dL), serum M-protein increase \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute increase \>=200mg/24h), appearance of new lesion(s),\>=50% increase from nadir in SPD of \>1 lesion or \>=50% increase in the longest diameter of a previous lesion \>1 cm in short axis or \>=50% increase in circulating plasma cells (minimum of 200 c/mcL) if that was the only measure of disease.
| months | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W |
|---|---|---|---|
| Phase 2: Progression Free Survival (PFS) | 2.89 (1.971 to 3.811) | 3.75 (1.971 to 5.881) | 3.02 (2.793 to 5.158) |
OS was defined as the time interval from the date of randomization to death from any cause. Participants without death prior to the analysis cut-off date were censored at the last date the participant was known to be alive or the cut-off date, whichever came first. The results provided below corresponds to descriptive OS information at the time of primary analysis completion date of 09 October 2019.
| months | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W |
|---|---|---|---|
| Phase 2: Overall Survival (OS) | NA (7.622 to NA) | NA (6.801 to NA) | 12.78 (7.392 to NA) |
Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of Ceoi. It was calculated using non-compartmental analysis (NCA) after the first administration in Cycle 1. The PK population was defined independently for isatuximab and cemiplimab and consisted of all participants from the all-treated (AT) population with at least 1 available concentration post-baseline (whatever the cycle and even if dosing was incomplete) with adequate documentation of dosing and sampling dates and times.
| microgram (mcg)/mL | Phase 2: Isatuximab | Phase 1 and 2: Combination Arm: Isatuximab + Cemiplimab |
|---|---|---|
| Phase 1 and 2: Plasma Concentration Observed at the End of IV Infusion (Ceoi) of Isatuximab Alone and in Combination With Cemiplimab | 255 ± 72.1 | 239 ± 67.7 |
Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of Cmax. It was calculated using NCA after the first administration in Cycle 1.
| mcg/mL | Phase 2: Isatuximab | Phase 1 and 2: Combination Arm: Isatuximab + Cemiplimab |
|---|---|---|
| Phase 1 and 2: Maximum Observed Concentration (Cmax) of Isatuximab Alone and in Combination With Cemiplimab | 264 ± 68.0 | 247 ± 65.9 |
Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of tmax. It was calculated using NCA after the first administration in Cycle 1.
| hour | Phase 2: Isatuximab | Phase 1 and 2: Combination Arm: Isatuximab + Cemiplimab |
|---|---|---|
| Phase 1 and 2: Time to Reach Cmax (Tmax) of Isatuximab Alone and in Combination With Cemiplimab | 5.56 (3.25 to 10.50) | 4.85 (2.58 to 13.70) |
Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of Clast. It was calculated using NCA after the first administration in Cycle 1.
| mcg/mL | Phase 2: Isatuximab | Phase 1 and 2: Combination Arm: Isatuximab + Cemiplimab |
|---|---|---|
| Phase 1 and 2: Last Concentration Observed Above the Lower Limit of Quantitation (Clast) of Isatuximab Alone and in Combination With Cemiplimab | 85.7 ± 44.9 | 64.1 ± 32.1 |
Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of tlast. It was calculated using NCA after the first administration in Cycle 1.
| hour | Phase 2: Isatuximab | Phase 1 and 2: Combination Arm: Isatuximab + Cemiplimab |
|---|---|---|
| Phase 1 and 2: Time of Clast (Tlast) of Isatuximab Alone and in Combination With Cemiplimab | 155.00 (72.40 to 169.00) | 165.00 (70.20 to 239.00) |
AUClast was defined as the area under the plasma concentration versus time curve from time 0 to real time tlast calculated using the trapezoidal method over the dosing interval after the first administration in Cycle 1.
| (mcg*hour)/mL | Phase 2: Isatuximab | Phase 1 and 2: Combination Arm: Isatuximab + Cemiplimab |
|---|---|---|
| Phase 1 and 2: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Tlast (AUClast) of Isatuximab Alone and in Combination With Cemiplimab | 21000 ± 7220 | 20200 ± 6590 |
AUC1week was defined as the area under the plasma concentration versus time curve from time 0 to 1 week post dose calculated using the trapezoidal method over the dosing interval after the first administration in Cycle 1.
| (mcg*hour)/mL | Phase 2: Isatuximab | Phase 1 and 2: Combination Arm: Isatuximab + Cemiplimab |
|---|---|---|
| Phase 1 and 2: AUC From Time 0 to Week 1 (AUC1week) of Isatuximab Alone and in Combination With Cemiplimab | 23000 ± 7250 | 21100 ± 6450 |
ADA responses were categorized as treatment-induced ADA and treatment boosted ADA. Pre-existing ADA was defined as ADA that were present in samples drawn during the pre-treatment period. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. The ADA evaluable population was defined independently for isatuximab and cemiplimab and consisted of all participants from AT population with at least 1 ADA result (negative, positive, or inconclusive) post-baseline.
| Participants | Phase 2: Isatuximab | Phase 1 and 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W |
|---|---|---|---|
| Pre-existing ADA | 0 | 1 | 0 |
| Treatment-induced | 0 | 0 | 0 |
| Treatment boosted | 0 | 0 | 0 |
ADA responses were categorized as treatment-induced ADA and treatment boosted ADA. Pre-existing ADA was defined as ADA that were present in samples drawn during the pre-treatment period. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer.
| Participants | Phase 1 and 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W |
|---|---|---|
| Pre-existing ADA | 1 | 0 |
| Treatment-induced | 2 | 0 |
| Treatment boosted | 0 | 0 |
Collected over TEAEs were collected from the first dose up to 30 days after the last dose of study treatment, approximately 50 months. All-Cause Mortality was reported for the whole study duration, approximately 62 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Isatuximab+Cemiplimab Q2W | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 2: Isatuximab | 20/33 (60.6%) | 17/33 (51.5%) | 31/33 (93.9%) |
| Phase 2: Isatuximab + CemiplimabQ2W | 23/37 (62.2%) | 17/37 (45.9%) | 34/37 (91.9%) |
| Phase 2:Isatuximab + CemiplimabQ4W | 22/35 (62.9%) | 21/35 (60%) | 27/35 (77.1%) |
| Event | Phase 1: Isatuximab+Cemiplimab Q2W | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2:Isatuximab + CemiplimabQ4W |
|---|---|---|---|---|
| Back PainMusculoskeletal and connective tissue disorders | 1/3 | 1/33 | 0/37 | 1/35 |
| PneumoniaInfections and infestations | 0/3 | 2/33 | 1/37 | 5/35 |
| InfluenzaInfections and infestations | 0/3 | 3/33 | 0/37 | 0/35 |
| Acute Kidney InjuryRenal and urinary disorders | 0/3 | 3/33 | 2/37 | 2/35 |
| PyrexiaGeneral disorders | 0/3 | 0/33 | 3/37 | 0/35 |
| Pulmonary SepsisInfections and infestations | 0/3 | 0/33 | 0/37 | 2/35 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/3 | 1/33 | 0/37 | 2/35 |
| Disease ProgressionGeneral disorders | 0/3 | 1/33 | 1/37 | 2/35 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 0/3 | 0/33 | 0/37 | 2/35 |
| Septic ShockInfections and infestations | 0/3 | 0/33 | 2/37 | 1/35 |
| Event | Phase 1: Isatuximab+Cemiplimab Q2W | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2:Isatuximab + CemiplimabQ4W |
|---|---|---|---|---|
| Infusion Related ReactionInjury, poisoning and procedural complications | 2/3 | 18/33 | 15/37 | 15/35 |
| PneumoniaInfections and infestations | 1/3 | 1/33 | 2/37 | 2/35 |
| SinusitisInfections and infestations | 1/3 | 0/33 | 3/37 | 0/35 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/3 | 4/33 | 4/37 | 7/35 |
| Decreased AppetiteMetabolism and nutrition disorders | 1/3 | 3/33 | 4/37 | 2/35 |
| LethargyNervous system disorders | 1/3 | 0/33 | 0/37 | 0/35 |
| NeuralgiaNervous system disorders | 1/3 | 0/33 | 1/37 | 0/35 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/3 | 5/33 | 5/37 | 2/35 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 1/3 | 0/33 | 0/37 | 1/35 |
| Dyspnoea ExertionalRespiratory, thoracic and mediastinal disorders | 1/3 | 1/33 | 1/37 | 0/35 |
Phase 1:The Safety population: All screened participants who received at least 1 dose or a part of a dose of study treatments (isatuximab or cemiplimab), regardless of the amount of treatment administered. Phase 2: The Randomized population: All participants who gave informed consent, were assigned randomization number by interactive response technology (IRT), regardless of whether they received any study treatment or received a different study treatment from which they were randomized.
| Age, Continuous(years) | Phase 1: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W | Total |
|---|---|---|---|---|---|
| Mean | 64.7 ± 2.9 | 66.1 ± 9.3 | 63.7 ± 10.0 | 66.4 ± 9.2 | 65.4 ± 9.4 |
| Sex: Female, Male(Participants) | Phase 1: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W | Total |
|---|---|---|---|---|---|
| Female | 1 | 16 | 14 | 16 | 47 |
| Male | 2 | 18 | 22 | 20 | 62 |
| Race (NIH/OMB)(Participants) | Phase 1: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab | Phase 2: Isatuximab + CemiplimabQ2W | Phase 2: Isatuximab + CemiplimabQ4W | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 3 | 3 | 8 |
| White | 3 | 29 | 30 | 29 | 91 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 3 | 3 | 3 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Feb 2018 to primary completion in Apr 2023, 61 months.
Results were first posted in Jun 2024, 1 year 2 months after primary completion.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 61 months is close to that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab